CombinatoRx (CRXX) Posts Q3 Loss, Better Y/Y
More News related to CRXX
- CombinatoRx, Inc. (CRXX) and Neruomed Pharma Receive U.S. FDA Letter Regarding NDA for Exalgo
- FDA Extends NDA Review for Exalgo(TM) Extended-Release Tablets
- Unusual 11 Mid-Day Movers 11/16: SPEX, NLST, DRAM, XJT Higher; PARD, CRXX, CAEI, CHIO Lower
- Morning Movers 11/16: SPEX, NLST, XJT, NABI, KHD, IBKC, SPA Higher; PARD, CRXX, CAEI Lower
- Biotech Movers: SPEX, NABI, ALKS Up; PARD, CRXX Down
More News related to Earnings
- Peet's (PEET) Moving Even Lower as Cowen Issues Mid-Day Downgrade
- RBC Downgrades Cephalon (CEPH) Following Cinquil Trial Results; Sees 'Little Momentum' Behind the Stock
- BMO Capital Downgrades Terra Industries (TRA) to Market Perform
- FTN Equity Downgrades Momenta Pharmaceuticals (MNTA) to Neutral
- Sterne Agee Downgrades Shoe Apparel Stores FINL & FL
CombinatoRx, Incorporated (NASDAQ: CRXX) reports Q3 loss of $0.24, compared to ($0.45) in the same quarter last year. Revenue for the quarter was $2.7 million, versus $3.0 million in Q308.
Related Categories
EarningsStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
